论文部分内容阅读
目的:检测子宫内膜异位症患者外周血及腹腔液中可溶性CD146(sCD146)水平并探讨其临床意义。方法:收集36例临床病理诊断明确的子宫内膜异位症患者和36例对照患者的血清及腹腔液,应用酶联免疫法(ELISA)检测血清及腹腔液sCD146的表达水平。结果:子宫内膜异位症患者外周血中sCD146的水平在整个月经周期(563.6±275.0)、增殖期(488.9±201.8)、分泌期(600.9±304.1)的表达均高于对照组的整个月经周期(376.2±133.5)、增殖期(351.9±81.9)、分泌期(410.3±183.5)的表达,差异有统计学意义(P<0.01)。子宫内膜异位症患者腹腔液中sCD146的水平在整个月经周期(844.1±264.1)、增殖期(1013.3±295.6)、分泌期(759.5±208.0)的表达均高于对照组的整个月经周期(536.4±221.1)、增殖期(564.9±237.0)、分泌期(496.6±202.1)的表达,差异有统计学意义(P<0.01);血清和腹腔液中两组分泌期和增殖期的表达均无统计学差异(P>0.05)。腹腔液各个周期的sCD146水平均高于外周血。结论:sCD146参与了子宫内膜异位症的发生和发展过程,无周期性的变化,表达较稳定。因此针对sCD146的检测和拮抗治疗很可能成为临床诊断和治疗该病的一种新途径。
Objective: To detect the levels of soluble CD146 (sCD146) in peripheral blood and peritoneal fluid of patients with endometriosis and to explore its clinical significance. Methods: Serum and peritoneal fluid were collected from 36 patients with clinically and pathologically diagnosed endometriosis and 36 controls. Serum and peritoneal fluid sCD146 expression levels were detected by enzyme-linked immunosorbent assay (ELISA). Results: The levels of sCD146 in the peripheral blood of patients with endometriosis were significantly higher than those in the control group during the entire menstrual cycle (563.6 ± 275.0), proliferative phase (488.9 ± 201.8), and secretory phase (600.9 ± 304.1) (376.2 ± 133.5), proliferative phase (351.9 ± 81.9), and secretory phase (410.3 ± 183.5), the difference was statistically significant (P <0.01). The level of sCD146 in peritoneal fluid of patients with endometriosis was higher than that of the control group in the whole menstrual cycle (844.1 ± 264.1), proliferative phase (1013.3 ± 295.6) and secretory phase (759.5 ± 208.0) 536.4 ± 221.1), proliferative phase (564.9 ± 237.0) and secretory phase (496.6 ± 202.1) (P <0.01). There was no significant difference in the secretory phase and proliferative phase between serum and peritoneal fluid Statistical difference (P> 0.05). Peritoneal fluid sCD146 levels of each cycle were higher than peripheral blood. Conclusion: sCD146 is involved in the occurrence and development of endometriosis, with no periodic changes and stable expression. Therefore, the detection and antagonistic treatment of sCD146 is likely to become a new way of clinical diagnosis and treatment of the disease.